Skip to main content
Premium Trial:

Request an Annual Quote

Bioinformatics Briefs: Jan 16, 2009

Premium

Protein Forest Opens UK Office

Protein Forest announced last week its European division is to be headquartered in Newcastle upon Tyne, UK.

The Lexington, Mass.-based proteomics technologies firm that manufactures fractionation technology said that the new European base will include office space and lab facilities to support sales, product demonstrations, applications development, and collaborative efforts with European partners.

The new office is led by European Business Director Robert Marchmont, who joined Protein Forest from GE Healthcare where he was focused on proteomics technologies, according to a statement. Russell Garlick, president and CEO of Protein Forest, said in a statement that Marchmont would be responsible for setting up dedicated sales and customer support teams and distribution networks within Europe.

Protein Forest's primary products bioinformatics products for mass spec experiments and its digital ProteomeChip sample prep technology for mass spectrometry-based proteomics.


Jubilant and BioLeap Partner in Drug Discovery

Jubilant Biosys, the Bangalore, India-based subsidiary of drug discovery service provider Jubilant Organosys, is partnering with BioLeap of New Hope, Penn., to combine BioLeap's computational fragment-based drug design platform with Jubilant's chemistry, biology, and crystallography services to create a preclinical drug development platform.

Jubilant Biosys has a 120,000-square-foot laboratory with over 300 scientists. The partnership will provide customers with integrated pre-clinical drug discovery services from lead identification and optimization to investigational new drug candidate selection for multiple therapeutic areas.

"This partnership leverages and combines the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development with BioLeap's leading edge computational fragment-based design capabilities, to deliver high quality, cost-effective pre-clinical drug discovery services," Gerald Evans, BioLeap chief business officer, said in a statement.

BioLeap's computational platform technology for fragment-based drug design includes a 3D design tool to help predict binding information and guide drug designers as they create novel molecules or improve upon existing molecules.


Schering-Plough Licenses Symyx Electronic Lab Notebook

Symyx announced that Schering-Plough has licensed Symyx Notebook to provide Schering-Plough research scientists with an enterprise-wide electronic lab notebook for the firm's R&D operations.

Schering-Plough will also collaborate with Symyx to develop within the Symyx Notebook a commercial metrology module built on the Symyx Lab Operational Informatics platform, the firm announced. The metrology module will enable researchers to track and manage equipment usage and calibration directly within their Notebook workflows.

Symyx Notebook is an ELN that consolidates experimental data from multiple domains, creating documents that can be shared and searched.


Tessella Adds Definiens Software to IT Services

IT consulting firm Tessella announced a partnership with image informatics firm Definiens to integrate Definiens' XD image-analysis software within the IT infrastructure of pharmaceutical and biotech companies that it did not identify.

Definiens said that Tessella also will independently market software that integrates the Definiens Cognition Network Technology, which is used to extract information from images.

"The partnership will expand our access to new markets and allow us to pursue larger clients for our premiere imaging-analysis technology," Manfred Voglmaier, Definiens' vice president of business development, said in a statement.

Financial terms of the deal were not disclosed.

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.